Collegium Pharmaceutical (COLL) FCF Margin (2016 - 2026)

Collegium Pharmaceutical's FCF Margin history runs 11 years deep, the most recent figure standing at 29.41% for Q1 2026.

• On a quarterly basis, FCF Margin fell 131.0% year-over-year to 29.41% in Q1 2026; TTM through Mar 2026 was 41.6%, a 349.0% increase from a year earlier, with the FY2025 full-year figure at 42.15%, up 972.0% from the prior year.
• FCF Margin eased to 29.41% in Q1 2026 per COLL's latest filing, from 60.25% in the prior quarter.
• Across five years, FCF Margin topped out at 229.71% in Q4 2024 and bottomed at 30.36% in Q1 2022.
• The 5-year median for FCF Margin is 38.5% (2025), against an average of 46.25%.
• Across the five-year window, FCF Margin jumped 18084 bps in 2024 and slumped 16946 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 46.49% in 2022, then rose by 5 bps to 48.87% in 2023, then jumped by 370 bps to 229.71% in 2024, then slumped by 74 bps to 60.25% in 2025, then plunged by 51 bps to 29.41% in 2026.
• Per Business Quant, the three latest COLL FCF Margin figures stand at 29.41% (Q1 2026), 60.25% (Q4 2025), and 37.38% (Q3 2025).